This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ETTX Entasis Therapeutics (ETTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Entasis Therapeutics Stock (NASDAQ:ETTX) 30 days 90 days 365 days Advanced Chart Get Entasis Therapeutics alerts:Sign Up Key Stats Today's Range$2.19▼$2.1950-Day Range$2.18▼$2.2052-Week Range$1.40▼$3.88Volume800 shsAverage Volume239,104 shsMarket Capitalization$104.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc. Read More Receive ETTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ETTX Stock News HeadlinesHedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJuly 18, 2022 | insidermonkey.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.July 28 at 2:00 AM | Brownstone Research (Ad)Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 9, 2022 | apnews.comAScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXJune 3, 2022 | apnews.comASHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 31, 2022 | apnews.comABiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesMay 25, 2022 | finance.yahoo.comSee More Headlines ETTX Stock Analysis - Frequently Asked Questions How were Entasis Therapeutics' earnings last quarter? Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.26). When did Entasis Therapeutics IPO? Entasis Therapeutics (ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers. What other stocks do shareholders of Entasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entasis Therapeutics investors own include Sorrento Therapeutics (SRNE), VYNE Therapeutics (VYNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), CymaBay Therapeutics (CBAY), Dynavax Technologies (DVAX) and Pfizer (PFE). Company Calendar Last Earnings11/04/2021Today7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ETTX CIK1724344 Webwww.entasistx.com Phone(781) 810-0120FaxN/AEmployees51Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-145.48% Return on Assets-103.75% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$7 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.32Miscellaneous Outstanding Shares47,852,000Free Float44,742,000Market Cap$104.80 million OptionableNot Optionable Beta1.33 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ETTX) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredIs America’s Everything Bubble About to Burst?On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTop 10 Green Zone Stocks to Buy NowOthers have paid $2,000 for access to stock picks like these—this weekend, you can get them free. Using a p...TradeSmith | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.